Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$4.20
-$0.13(-3.36%)
At close: 4:00 PM EST
$4.20
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)1.57M
Market Cap
$413.99M
Enterprise Value$178.85M
Total Cash (Recent Filing)$270.93M
Total Debt (Recent Filing)$4.23M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 18, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.44
Shares Outstanding114,046,196
10 Day Avg. Volume2,006,761
30 Day Avg. Volume1,567,192
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue289.41
Enterprise Value/Gross Profit-59.09
Enterprise Value/Ebitda-1.62
Forecast
1Y Price Target
$13.33Price Target Upside217.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.11
Revenue Forecast (FY)$389.33K
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Low LeveragePerspective's extremely low leverage and sizable equity provide durable financial flexibility to fund multi-year clinical programs and manufacturing buildouts. Low debt reduces refinancing and covenant risk, preserving optionality for partnerships or capital deployment while clinical milestones mature.
Robust Interim Clinical Efficacy And TolerabilityInterim 212Pb program readouts showing deepening responses and favorable safety materially de-risk the scientific thesis. Durable efficacy with limited high-grade toxicity supports dose escalation, registration pathways and makes the pipeline more attractive to partners or acquirers over the medium term.
Vertical Manufacturing And Regional Supply StrategyBuilding regional manufacturing and a vertically integrated supply chain reduces product availability risk and supports reliable, ready-to-administer hospital delivery. This infrastructure strengthens commercialization readiness and can create a sustainable competitive advantage in radiopharmaceutical logistics.
Bears Say
Minimal Commercial Revenue And Large Net LossesCurrent revenue is negligible while operating at very large structural losses, indicating the company remains years from meaningful commercial sales. Persistent negative margins mean value realization depends on successful clinical outcomes and market adoption, raising execution risk for investors.
High Cash Burn And Negative Cash GenerationSustained operating and free cash outflows reflect heavy investment in R&D and manufacturing. Continued negative cash generation increases reliance on external financing or partnerships, raising dilution and refinancing risk and constraining strategic flexibility if clinical progress slows.
Near-term Revenue Reliance On Legacy Device Business And Capital RaisesNear-term receipts stem from a legacy brachytherapy device business while core radiopharmaceutical revenue is not yet established. Dependence on non-core device sales and periodic capital raises leaves the firm exposed to execution risk during the transition to scalable radiopharma commercialization.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics, Inc.’s price range in the past 12 months?
Perspective Therapeutics, Inc. lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics, Inc.’s market cap?
Perspective Therapeutics, Inc.’s market cap is $413.99M.
When is Perspective Therapeutics, Inc.’s upcoming earnings report date?
Perspective Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 45 days.
How were Perspective Therapeutics, Inc.’s earnings last quarter?
Perspective Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Perspective Therapeutics, Inc. overvalued?
According to Wall Street analysts Perspective Therapeutics, Inc.’s price is currently Undervalued.
Does Perspective Therapeutics, Inc. pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
What is Perspective Therapeutics, Inc.’s EPS estimate?
Perspective Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Perspective Therapeutics, Inc. have?
Perspective Therapeutics, Inc. has 114,046,196 shares outstanding.
What happened to Perspective Therapeutics, Inc.’s price movement after its last earnings report?
Perspective Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -2.835%.
Which hedge fund is a major shareholder of Perspective Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (217.46% Upside)
$13.33 (217.46% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 80.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.07%
12-Months-Change
Fundamentals
Return on Equity
-41.84%
Trailing 12-Months
Asset Growth
24.72%
Trailing 12-Months
Company Description
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$13.33
▲(217.46% Upside)
Technical Analysis
Ownership Overview
1.63% Insiders
6.91% Mutual Funds
35.26% Other Institutional Investors
42.58% Public Companies and Individual Investors